Retatrutide: The Triple-Agonist Weight Loss Drug Coming to South Africa (2026 Guide)

If you have been following the GLP-1 weight loss revolution, you have probably heard of Ozempic and Mounjaro. But there is a new player that could change everything: retatrutide, a triple-agonist drug from Eli Lilly that has delivered the most dramatic weight loss results ever seen in clinical trials.

In this guide, we break down what retatrutide is, how it works, when South Africans might be able to get it, what it could cost, and how it stacks up against the GLP-1 drugs already available at SA pharmacies.

What Is Retatrutide?

Retatrutide (development code LY3437943) is an injectable medication being developed by Eli Lilly -- the same company behind Mounjaro (tirzepatide). What makes retatrutide unique is that it is a triple hormone receptor agonist, targeting three different pathways simultaneously:

• GLP-1 (glucagon-like peptide-1) -- the same pathway targeted by Ozempic and Wegovy. Reduces appetite and slows stomach emptying.
• GIP (glucose-dependent insulinotropic polypeptide) -- also targeted by Mounjaro. Enhances insulin sensitivity and may boost fat burning.
• Glucagon receptor -- this is the new addition. Glucagon increases energy expenditure, promotes fat breakdown, and may reduce liver fat.

Think of it this way: Ozempic pulls one lever, Mounjaro pulls two, and retatrutide pulls all three. The result is a compounding effect on both appetite suppression and metabolic rate.

Clinical Trial Results: How Much Weight Can You Lose?

The Phase 2 trial results, published in the New England Journal of Medicine in 2023, were remarkable. Here is how retatrutide performed across different doses over 48 weeks:

Phase 3 trials (the final stage before regulatory approval) are currently underway under the programme name TRIUMPH. Results are expected to be reported through 2026 and into 2027.

Retatrutide vs Ozempic vs Mounjaro: How Do They Compare?

South Africans currently have access to Ozempic (semaglutide) and are starting to see Mounjaro (tirzepatide) enter the market. Here is how retatrutide compares:

The glucagon receptor component is what sets retatrutide apart. While GLP-1 and GIP mainly work on appetite and insulin, glucagon directly increases the body's energy expenditure -- essentially helping you burn more calories even at rest. Early data also suggests retatrutide may be particularly effective at reducing visceral fat and liver fat.

When Will Retatrutide Be Available in South Africa?

Here is the realistic timeline:

1. 2026: Phase 3 (TRIUMPH) trial data continues to be reported. If results confirm Phase 2 findings, Eli Lilly will submit for regulatory approval.
2. Late 2026 / Early 2027: Possible FDA approval in the United States (earliest scenario).
3. 2027-2028: SAHPRA submission and review. SAHPRA typically takes 12-24 months after a manufacturer submits a dossier. South Africa sometimes follows faster when there is strong international precedent.
4. 2028 (optimistic) to 2029: Potential SA market availability.

Side Effects: What to Expect

Based on Phase 2 trial data, the most common side effects of retatrutide are similar to other GLP-1 drugs but tend to be more frequent at higher doses:

• Nausea -- reported by up to 45% of participants at the 12 mg dose (usually mild, improving over weeks)
• Diarrhoea -- common in the first weeks of treatment
• Vomiting -- more common than with semaglutide alone
• Constipation -- affects some users
• Decreased appetite -- this is partly the intended effect, but can be uncomfortable initially

The dose-escalation protocol (starting low and gradually increasing) is designed to minimise these side effects. Most participants who stayed on treatment reported that GI symptoms improved significantly after the first 4-8 weeks.

Serious side effects were rare in Phase 2 trials. As with all GLP-1 class medications, there are theoretical concerns about pancreatitis and thyroid issues, but these were not observed at elevated rates. Phase 3 trials with larger participant numbers will provide clearer safety data.

Estimated Cost in South Africa

While no official pricing exists for the South African market, we can make educated estimates based on how Eli Lilly has priced Mounjaro internationally:

• US pricing: Mounjaro launched at roughly $1,000-$1,200/month in the US. Retatrutide is expected to be priced similarly or slightly higher.
• SA conversion: Factoring in exchange rates, import duties, and the SEP (Single Exit Price) system, monthly costs of R4,000 to R7,000 are a reasonable estimate.
• Medical aid: Coverage will depend on whether SAHPRA classifies it for obesity or diabetes treatment, and individual scheme formularies. Currently, medical aid coverage for GLP-1 drugs in SA is inconsistent -- some schemes cover semaglutide for diabetes but not weight loss.

For comparison, Ozempic currently costs between R3,000 and R5,500 per month at SA pharmacies like Dis-Chem and Clicks, depending on the dose.

Beyond Weight Loss: Other Potential Benefits

The TRIUMPH clinical programme is also investigating retatrutide for several conditions beyond obesity:

• Type 2 diabetes -- strong glucose-lowering effects observed in Phase 2
• Non-alcoholic fatty liver disease (NAFLD/MASH) -- the glucagon component shows particular promise for reducing liver fat; one sub-study showed a 42% reduction in liver fat
• Cardiovascular risk reduction -- following the path of semaglutide's SELECT trial
• Sleep apnoea -- significant weight loss typically improves sleep quality and may resolve obstructive sleep apnoea

Should You Wait for Retatrutide?

This is a question many South Africans are asking. Here is a practical framework:

• If you need to lose weight now: Do not wait. Current options like Ozempic, Wegovy, and Mounjaro are available and effective. A 15-21% weight loss is still life-changing. Combine with a solid diet plan and regular exercise.
• If you have tried GLP-1 drugs and plateaued: Retatrutide could be a future option worth discussing with your endocrinologist when it becomes available.
• If you prefer non-medication approaches: Focus on proven strategies -- calorie deficit, high protein intake, strength training, and mindset work. These remain the foundation regardless of any medication.

Key Takeaways

• Retatrutide is a triple-agonist (GLP-1 + GIP + glucagon) weight loss drug from Eli Lilly
• Phase 2 trials showed up to 24.2% body weight loss over 48 weeks -- the highest ever recorded for a weight loss medication
• It is not yet available in South Africa -- earliest realistic availability is 2028
• Estimated SA cost: R4,000 - R7,000/month (subject to change)
• Side effects are similar to other GLP-1 drugs but may be more intense at higher doses
• Do not wait -- effective options are available now. Speak to your doctor about the best approach for your situation